Esperoct
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Haemophilia A
Conditions
Haemophilia A
Trial Timeline
Nov 23, 2022 → Jun 30, 2026
NCT ID
NCT05621746About Esperoct
Esperoct is a pre-clinical stage product being developed by Novo Nordisk for Haemophilia A. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05621746. Target conditions include Haemophilia A.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05621746 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Haemophilia A
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mim8 | Novo Nordisk | Phase 3 | 76 |
| Turoctocog alfa | Novo Nordisk | Phase 3 | 76 |
| NNC0365-3769 (Mim8) | Novo Nordisk | Phase 3 | 76 |
| Turoctocog alfa pegol | Novo Nordisk | Pre-clinical | 22 |
| Mim8 B, 10 mg/mL + Mim8 B, 100 mg/mL + Mim8 B, placebo | Novo Nordisk | Phase 1 | 32 |
| Turoctocog alfa pegol | Novo Nordisk | Pre-clinical | 22 |
| Concizumab | Novo Nordisk | Phase 3 | 76 |
| Concizumab | Novo Nordisk | Phase 3 | 76 |
| turoctocog alfa pegol (N8-GP) | Novo Nordisk | Phase 3 | 76 |
| Concizumab | Novo Nordisk | Phase 3 | 76 |
| NNC0442-0344 A | Novo Nordisk | Phase 1 | 32 |
| NNC0365-3769 (Mim8) PPX | Novo Nordisk | Phase 3 | 76 |
| Concizumab | Novo Nordisk | Pre-clinical | 22 |
| Refixia® | Novo Nordisk | Pre-clinical | 22 |
| NNC0442-0344 A + Placebo | Novo Nordisk | Phase 1 | 32 |
| Mim8 | Novo Nordisk | Phase 3 | 76 |
| Turoctocog alfa pegol (N8-GP) | Novo Nordisk | Pre-clinical | 22 |
| Nonacog beta pegol | Novo Nordisk | Pre-clinical | 22 |
| Concizumab | Novo Nordisk | Pre-clinical | 22 |
| Turoctocog alfa | Novo Nordisk | Pre-clinical | 22 |